Characterization of orofacial features in sclerodermatous chronic graft-versus-host disease

被引:1
|
作者
Bajonaid, Amal [1 ,12 ]
Guntaka, Praveen Kumar [2 ]
Harper, Matthew [3 ,4 ]
Cutler, Corey [5 ]
Duncan, Christine [6 ]
Villa, Alessandro [7 ,8 ,9 ]
Sroussi, Herve Y. [10 ,11 ]
Woo, Sook-Bin [10 ,11 ]
Treister, Nathaniel S. [10 ,11 ]
机构
[1] Jazan Univ, Coll Dent, Jazan, Saudi Arabia
[2] Mt Sinai Hlth Syst, New York, NY USA
[3] Harvard Sch Dent Med, Dept Dev Biol, Boston, MA USA
[4] Boston Childrens Hosp, Dept Dent, Boston, MA USA
[5] Dana Farber Canc Inst, Div Stem Cell Transplantat & Cellular Therapy, Boston, MA USA
[6] Dana Farber Boston Childrens Canc & Blood Disorder, Boston, MA USA
[7] Univ Calif San Francisco, Dept Orofacial Sci, San Francisco, CA USA
[8] Herbert Wertheim Coll Med, Miami, FL USA
[9] Miami Canc Inst, Miami, FL USA
[10] Harvard Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA USA
[11] Brigham & Womens Hosp, Div Oral Med & Dent, Boston, MA USA
[12] Jazan Univ, Coll Dent, Dept Oral & Maxillofacial Surg & Diagnost Sci, Al Maarefah Rd, Jazan, Saudi Arabia
关键词
face; graft-versus-host disease; oral cavity; sclerosis; CONSENSUS DEVELOPMENT PROJECT; RISK-FACTORS; PHOTOBIOMODULATION THERAPY; CELL TRANSPLANTATION; ORAL INVOLVEMENT; CLINICAL-TRIALS; CHRONIC GVHD; RECOMMENDATIONS; CRITERIA; PATHOGENESIS;
D O I
10.1111/odi.14932
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
BackgroundChronic graft-versus-host disease (cGVHD) is a leading cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (alloHCT). The sclerodermatous form of cGVHD can be particularly debilitating; however, orofacial sclerodermatous involvement remains poorly described. ObjectiveTo characterize orofacial features of sclerodermatous cGVHD in a single center cohort of patients who underwent alloHCT. Study DesignRetrospective data were collected from electronic medical records and analyzed descriptively. ResultsThere were 39 patients who received alloHCT between 1993 and 2017 and developed orofacial sclerodermatous cGVHD. Concomitant cutaneous sclerodermatous cGVHD was common (n = 20, 51%). Orofacial sclerodermatous cGVHD features included fibrous bands of the buccal mucosa (n = 23, 59%), limited mouth opening (n = 19, 54%), perioral fibrosis (n = 8, 21%), and focal gingival recession (n = 4, 10%). Oral mucosal fibrosis was observed at the site of active or resolved chronic lichenoid inflammation in 30 patients, with all but two also presenting with a history of ulcerations. Management included jaw stretching exercises (n = 10; 6 stable/improved), surgery (n = 3; 2 improved), and intralesional corticosteroid injections (n = 2; 2 improved). ConclusionsOrofacial involvement with sclerodermatous cGVHD can present with multiple manifestations including fibrous banding, limited mouth opening, perioral fibrosis, and focal gingival recession. Surgical and non-surgical management strategies may improve clinical function and reduce morbidity.
引用
收藏
页码:5082 / 5090
页数:9
相关论文
共 50 条
  • [41] Sclerodermatous graft-versus-host disease: clinical spectrum and therapeutic challenges
    White, J. M. L.
    Creamer, D.
    du Vivier, A. W. P.
    Pagliuca, A.
    Ho, A. Y.
    Devereux, S.
    Salisbury, J. R.
    Mufti, G. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2007, 156 (05) : 1032 - 1038
  • [42] Hedgehog blockade in the treatment of steroid-refractory sclerodermatous chronic graft-versus-host disease
    Radojcic, Vedran
    Lee, Catherine
    Pletneva, Maria
    Hicks, Kolleen
    Sarantopoulos, Stefanie
    Couriel, Daniel
    BONE MARROW TRANSPLANTATION, 2019, 54 : 305 - 306
  • [43] SCLERODERMATOUS SKIN REACTION IN GRAFT-VERSUS-HOST DISEASE TREATED WITH THALIDOMIDE
    PEDAILLES, S
    TROUSSARD, X
    LAUNAY, V
    BAZIN, A
    SENTIAS, C
    SURBLED, M
    PRESSE MEDICALE, 1993, 22 (01): : 37 - 37
  • [44] Chronic graft-versus-host disease
    Rorvik, Synne Dragesund
    Abrahamsen, Ingerid Weum
    Myhre, Anders Eivind
    Vo, Camilla Dao
    Odegaard, Eva Meling
    Bruserud, Oystein
    Gedde-Dahl, Tobias
    Tvedt, Tor Henrik Anderson
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2023, 143 (04) : 337 - 341
  • [45] Chronic graft-versus-host disease
    Bolanos-Meade, Javier
    Vogelsang, Georgia B.
    CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (20) : 1974 - 1986
  • [46] Chronic graft-versus-host disease
    Galbizo, Ellaine
    Williams, Lori A.
    ONCOLOGY NURSING FORUM, 2006, 33 (05) : 881 - 883
  • [47] Chronic graft-versus-host disease
    Cutler, C
    Antin, JH
    CURRENT OPINION IN ONCOLOGY, 2006, 18 (02) : 126 - 131
  • [48] Chronic graft-versus-host disease
    Margolis, J
    Vogelsang, G
    JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2000, 9 (03): : 339 - 346
  • [49] CHRONIC GRAFT-VERSUS-HOST DISEASE
    ATKINSON, K
    BONE MARROW TRANSPLANTATION, 1990, 5 (02) : 69 - 82
  • [50] Chronic graft-versus-host disease
    Horwitz, ME
    Sullivan, KM
    BLOOD REVIEWS, 2006, 20 (01) : 15 - 27